Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: A systematic review and meta-analysis

Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer

“…In the present meta-analysis, we found the spectrum of DC-CIK immunotherapy associated AEs were generally consistent with previous studies [14,16,17,37]. Similar risks of all-grade anemia, leukopenia, dermatosis, diarrhea, nausea, acratia, and chest distress were observed in DC-CIK immunotherapy compared to control therapies (Table 3).…”

“…However, the analysis of ORR (RR: 1.190, 95% CI: 0.561-2.526, P = 0.650) showed no statistical significance, which was consistent with previous studies [16,17]. Subgroup analysis and meta-regression were not conducted due to little heterogeneity across studies and limited number of studies provided complete information.…”

“…However, the survival benefit of DC-CIK immunotherapy has been in argument, especially in long-term survival. Previous studies had reported that the analysis of 2-year PFS rate (RR: 1.08, 95 CI%: 0.98-1.19, P = 0.100) and 5-year survival rate (RR: 7.00, 95% CI: 0.39-124.14, P = 0.180) showed no statistical significance [16,17], probably as a result of the following reasons. paradoxically induce a temperate microenvironment for malignant cells growth, which is a major challenge for cancer immunotherapy [34].…”

“…But the results were inconsistent. A previous meta-analysis had reported that DC-CIK immunotherapy is a safe and effective treatment for patients with malignant tumors [16]. However, the meta-analysis included hepatic cancer, renal cancer, and NSCLC, not focused on NSCLC.…”

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

“…DC-activated CIK cells significantly enhanced antitumor activity, increased the ratio of CD3 + CD56 + cells, promoted cell proliferation, lessened cell apoptosis, and increased overall survival rates (Yang et al, 2013). These data are in harmony with results from other studies, which showed that DC-CIK therapy increased the survival rates and progression free survival, compared to placebo, no intervention, conventional treatments, or other complementary and alternative medicines (Chen et al, 2014). Yuanying et al also showed that combining cryosurgery, chemotherapy or DC therapy with activated CIK immunotherapy can help prolong the median overall survival of patients (Yuanying et al, 2013).…”